Stock Analysis

Chlitina Holding Third Quarter 2024 Earnings: EPS Beats Expectations

Published
TWSE:4137

Chlitina Holding (TWSE:4137) Third Quarter 2024 Results

Key Financial Results

  • Revenue: NT$1.02b (down 17% from 3Q 2023).
  • Net income: NT$125.8m (down 30% from 3Q 2023).
  • Profit margin: 12% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue.
  • EPS: NT$1.52 (down from NT$2.25 in 3Q 2023).
TWSE:4137 Earnings and Revenue Growth November 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chlitina Holding EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.1%.

Looking ahead, revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 9.1% growth forecast for the Personal Products industry in Asia.

Performance of the market in Taiwan.

The company's shares are down 7.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Chlitina Holding (of which 2 make us uncomfortable!) you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.